$LNAI

Lunai Bioworks (NASDAQ: LNAI) has entered an exclusive agreement with Tanaist to enhance its Parkinson's disease research platform. The collaboration aims to validate AI-identified patient subtypes with human cellular biology, potentially advancing biomarker and therapeutic target development. Lunai will have exclusive rights to Tanaist's technology for Parkinson's programs based on its patient phenoclusters.

Lunai Bioworks (Nasdaq: LNAI) announced a study by its subsidiary BioSymetrics, demonstrating AI-based chemical-risk screening for AI-generated compounds. The study achieved 5.1-fold enrichment in predicting acetylcholinesterase (AChE) inhibition, a relevant benchmark for chemical-hazard triage. The company aims to complement existing AI safeguards with structure-based screening, addressing dual-use risks in AI-enabled science. Lunai seeks collaborations with AI developers like OpenAI and Anthro

Lunai Bioworks (LNAI) filed a Second Amended Complaint in Delaware court, adding six broker-dealers and two principals as defendants. The suit alleges securities fraud and market manipulation under Rule 10b-5. The company is an AI-driven precision medicine platform focused on therapeutics and biodefense. The outcome of the lawsuit is uncertain, and the allegations have not been proven.

Lunai Bioworks (Nasdaq: LNAI) said it signed a definitive Master Collaboration Agreement with BrainStorm Therapeutics to develop precision neuroscience programs for Parkinson’s disease. Lunai’s BioSymetrics subsidiary published a white paper using the PPMI dataset to identify Parkinson’s subtypes and proteomic signatures. The companies target an initial data readout in 1H 2027.

Lunai Bioworks (Nasdaq: LNAI) said it filed a First Amended Complaint naming 10 defendants, including three FINRA broker dealers, in a naked short selling fraud suit. The company alleges 29.6 million failed-to-deliver shares and that failures to deliver exceeded 80% of shares outstanding from Nov 2025 to May 2026, citing a March 17 trade volume 15.3 times shares outstanding. It seeks treble damages under RICO and other relief.

uniQure (QURE) surged 78% after the FDA said the 3-year Phase I/II analysis for AMT-130 in Huntington’s could serve as primary evidence for an accelerated BLA; QURE plans to file in Q3 2026. Elicio (ELTX) rose 71% on Phase 2 AMPLIFY-7P responses. Lunai (LNAI) gained 40% on CEO updates; other biotech movers included CLPT, PLRZ and FTH.

Lunai Bioworks Inc. (LNAI) shares rose 56.77% to $4.46 on Wednesday after the company sent a shareholder letter detailing progress in its AI-driven biodefense and precision neurology businesses. The update cited its first revenue-generating multi-year U.S. government defense contract, expansion of the Pathfinder Consortium, neurology collaborations, and plans to pursue legal action over alleged naked short-selling. Volume was 19.41M vs 1.78M average.

Lunai Bioworks (NASDAQ: LNAI) said its CEO letter highlights progress in AI-enabled biodefense and precision neurology. In April 2026, it secured a multi-year, revenue-generating defense collaboration with BioSymetrics for chemical threat assessment. It also cites the Pathfinder Consortium with major universities and a $1.85 million Phase I/II STTR grant. The letter adds that it filed suit in May 2026 over alleged naked short selling, citing 29.6 million shares failing to deliver.

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

Lunai Bioworks announced it completed a $20 million preferred stock issuance to acquire intellectual property related to CNS delivery and neurotherapeutics. This acquisition adds two new methods to bypass the blood-brain barrier: a prodrug system and a nose-to-brain pathway, bolstering its programs for Alzheimer's and other neurological conditions. The company believes this transaction will also help it meet Nasdaq's minimum stockholder equity requirements.